| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Newport Pharmaceuticals International |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002060 |
Purpose
The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS. Secondly, to determine the effect of Isoprinosine in decreasing the severity and/or incidence of lesser opportunistic infections and/or other conditions associated with ARC.
| Condition | Intervention |
|
HIV Infections |
Drug: Inosine pranobex |
| MedlinePlus related topics: | AIDS Gay, Lesbian and Transgender Health |
| Drug Information available for: | Inosine Inosine pranobex |
| Study Type: | Interventional |
| Study Design: | Treatment, Double-Blind |
| Official Title: | A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC) |
Eligibility
| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Exclusion Criteria
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 1 month of study entry:
Prior Treatment:
Excluded within 1 month of study entry:
History of gout, uric acid urolithiasis, uric acid nephrolithiasis, or renal dysfunction.
Homosexual male patients with AIDS related complex (ARC).
Current IV drug abuse.
Contacts and Locations More Information
| Study ID Numbers: | 008D, ISO-111-USA |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002060 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
